Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian equity markets slip into red
Tue, 14 Oct 11:30 am

After opening firm, the Indian Indices slipped into red and have remained below the dotted line during the morning trading session. Majority of stocks are trading in red with realty and metal stocks leading the pack of losers. Only stocks from healthcare and capital goods sectors are witnessing buying interest.

The BSE-Sensex is trading down 65 points. The NSE-Nifty is trading down 26 points. However both midcap and small cap stocks are in favour. The BSE Mid Cap index is trading up 0.12% and the BSE Small Cap index is trading up 0.11%%. The rupee is trading at 61.24 to the US dollar.

Indian pharma stocks are trading mixed with Indoco Remedies and Divis laboratories being among the leading gainers in the pack, while Ipca labs and Panacea biotech are the leading losers. As per the financial daily, Ranbaxy laboratories, subsidiary in US Ranbaxy Inc is witnessing high resignations of the top management. Around 5 top executives including the country's head Venkatachalam Krishnan and other heads from various departments have resigned together in the last week. All these top heads were working with the company for more than 10 years. While no specific reason for this attrition is known so far. Reportedly, both the companies viz Sun pharma and Ranbaxy denied to comment on this development. One should note this move comes after few months the India' largest pharma company Sun pharma decided to acquire the former company.

Telecom stocks are trading mixed today. While Bharti Airtel is leading the gainers; Reliance Communications is among the top losers. As per a leading financial daily, the Bharti Airtel - Loop Mobile deal is now in limbo with the Department of Telecom (DoT) yet to clear the file. Loop has about 3 m customers in Mumbai and its license will expire on 29 November 2014. The company did not renew its license due to commercial reasons. Instead, it sold out to Bharti for Rs 7 bn earlier this year. However, the DoT has not cleared the sale as Loop still owes the department about Rs 8 bn. Bharti had asked Loop's customers to port out to its network by submitting KYC documents at its stores but the regulator TRAI had asked the company to stop the porting. As per TRAI, Bharti cannot force Loop's customers to port to the company's network at their own expense. Bharti has asked the government resolve the issue quickly. Bharti Airtel was trading up 1.5% at the time of writing.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian equity markets slip into red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.